阴道改变、性功能及困扰:EMBRACE阴道疾病亚组中局部晚期宫颈癌女性的前瞻性评估
EMBRACE阴道疾病亚组前瞻性评估113例IB1-IIIB期宫颈癌患者在接受影像引导放化疗及近距离治疗后的阴道改变与患者报告结局。约20%出现轻度阴道改变,47%在2年时无性生活;性活跃女性中约50%报告阴道或性功能问题及困扰,但重度问题比例低;医生评估的阴道改变与患者报告问题关联弱。
要点
- 影像引导放化疗及近距离治疗后阴道改变多为轻度(1级),约20%患者出现。
- 2年时47%患者无性生活,性活跃女性中约50%报告阴道或性功能问题及困扰。
- 医生评估的阴道改变与患者报告的阴道功能问题及性困扰关联弱或无。
核心结论
- 影像引导放化疗及近距离治疗后报告轻度阴道改变,可能与肿瘤阴道受累有限、EMBRACE特异性治疗优化和康复建议有关。
- 阴道及性功能问题和性困扰报告频繁,但重度问题及困扰比例低。
- 阴道改变与阴道功能问题及性困扰之间缺乏关联,提示性功能比单纯阴道疾病更复杂。
研究设计与样本
- EMBRACE阴道疾病亚组前瞻性研究,纳入113例IB1-IIIB期宫颈癌且阴道受累≤5 mm的患者。
- 采用CTCAE评估医生判定的阴道改变,使用经过验证的生活质量和性问卷评估患者报告结局。
- 统计分析采用广义线性混合模型和Spearman rho相关系数。
主要发现
- 随访期间约20%(范围11-37%)报告轻度(1级)阴道改变。
- 2年时47%无性生活。
- 性活跃女性中约50%随时间报告任何阴道及性功能问题和困扰;重度阴道问题、性问题和性困扰分别高达14%、20%和8%。
- 医生评估的阴道改变和患者报告性满意度在基线与首次随访间差异有统计学意义(p≤.05),此后无进一步显著变化。
- 医生评估的阴道改变与患者报告的阴道功能问题及性困扰间无关联或仅弱关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The EMBRACE-vaginal morbidity substudy prospectively evaluated physician-assessed vaginal changes and patient-reported-outcomes (PRO) on vaginal and sexual functioning problems and distress in the first 2-years after image-guided radio(chemo)therapy and brachytherapy for locally advanced cervical cancer. METHODS: Eligible patients had stage IB1-IIIB cervical cancer with ≤5 mm vaginal involvement. Assessment of vaginal changes was graded using CTCAE. PRO were assessed using validated Quality-of-Life and sexual questionnaires. Statistical analysis included Generalized-Linear-Mixed-Models and Spearman's rho-correlation coefficients. RESULTS: 113 eligible patients were included. Mostly mild (grade 1) vaginal changes were reported over time in about 20% (range 11-37%). At 2-years, 47% was not sexually active. Approximately 50% of the sexually active women reported any vaginal and sexual functioning problems and distress over time; more substantial vaginal and sexual problems and distress were reported by up to 14%, 20% and 8%, respectively. Physician-assessed vaginal changes and PRO sexual satisfaction differed significantly (p ≤ .05) between baseline and first follow-up, without further significant changes over time. No or only small associations between physician-assessed vaginal changes and PRO vaginal functioning problems and sexual distress were found. CONCLUSIONS: Mild vaginal changes were reported after image-guided radio(chemo)therapy and brachytherapy, potentially due to the combination of tumors with limited vaginal involvement, EMBRACE-specific treatment optimization and rehabilitation recommendations. Although vaginal and sexual functioning problems and sexual distress were frequently reported, the rate of substantial problems and distress was low. The lack of association between vaginal changes, vaginal functioning problems and sexual distress shows that sexual functioning is more complex than vaginal morbidity alone.
引用
- Suvaal I, Kirchheiner K, Nout RA, et al. Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy. Gynecol Oncol. 2023. PMID: 36682090. doi:10.1016/j.ygyno.2023.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。